先看重点
29名19-39岁的年轻人使用ANZEILAX-Green应用并配合智能手表8周后,GAD-7焦虑评分平均下降4.79分(95%置信区间-6.56至-3.02;P<.001)。研究没有对照组,评分下降可能源于预期、时间等因素,而不一定是应用的作用。
证据类型
研究论文
解读依据
公开摘要
阅读重点
方法与适用范围
研究在问什么
许多年轻人有焦虑却难以及时得到治疗。能在当下询问情绪的数字工具(生态瞬时评估与干预,EMA/EMI)可能有帮助,可穿戴数据又可使反馈更个性化。作者在真实环境中检验了ANZEILAX-Green的可行性与效果,该应用将EMA/EMI与智能手表的心率、睡眠和活动数据结合起来。
研究了谁,如何研究
为期8周的探索性混合方法实验研究,对象为19-39岁的年轻人,最终分析29人。参与者使用整合EMA/EMI模块的手机应用,并佩戴持续采集心率、睡眠和活动数据的智能手表。广泛性焦虑障碍7项量表(GAD-7)和患者健康问卷-9(PHQ-9)在基线及第2、4、6、8周测量,罗森伯格自尊量表(RSES)在基线和第8周测量。变化用配对t检验和重复测量方差分析检验,访谈做主题分析。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1GAD-7平均下降4.79分(95%置信区间-6.56至-3.02;Cohen d=1.03;P<.001);PHQ-9下降3.86分(-5.79至-1.93;d=0.76;P<.001);RSES上升5.21分(3.47至6.95;d=1.14;P<.001)。
- 2GAD-7在各次评估中持续改善,自第4周起下降具有统计学意义。
- 3依从性高:参与者完成了80%的EMA/EMI提示。
- 4可穿戴数据显示深睡眠增多、活动量减少的趋势,睡眠指标与抑郁症状显著相关。访谈归纳出5种机制:自我觉察增强、数据驱动的反思、行为改变、内在动机以及治疗向日常生活延伸。
局限与不确定性
- 1没有对照组,组内改善不能归因于应用或可穿戴数据。
- 2仅29人纳入分析,属探索性设计;摘要未说明开始时有多少人,也未说明是否确诊焦虑。
- 3焦虑和抑郁靠问卷自评,且参与者知道自己在接受干预。
- 4作者指出这一效果需要对照试验证实。本解读仅基于摘要。
对日常健康的启示
与智能手表配合的情绪打卡应用被这些年轻人较好地使用和接受,焦虑评分也下降了,但这不能证明是应用造成的。持续的焦虑问题应由临床医生或心理健康专业人员处理,而不是只靠应用。
如何联系自己的数据
智能手表记录了心率、睡眠和活动,8周内深睡眠和活动量有变化。如果你把情绪与睡眠、活动一起记录,请使用同一设备,看每周模式而不是单晚数据,并把睡眠与情绪的关联当作可以讨论的规律,而非诊断。
如何理解这类证据
索引未明确确定具体研究设计,应先读方法;核对人群、对照、结局和不确定性,再判断能否作因果解释。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
Young adults report high levels of anxiety, yet their access to timely treatment remains limited. Mobile-based digital therapeutics, particularly ecological momentary assessment and intervention (EMA/EMI), offer a promising approach to deliver context-responsive care. The integration of wearable-derived digital phenotypes with digital therapeutics may enhance the personalization of feedback in such interventions, but empirical evidence from real-world settings remains scarce.
Objective
This study examined the real-world applicability and effectiveness of an EMA/EMI-based digital therapeutic, ANZEILAX-Green (HAII Corp), for use in anxiety reduction in young adults and investigated how personalized feedback generated by combining EMA/EMI data with wearable-based digital phenotypes ameliorates symptoms and promotes self-management and user engagement.
Methods
An 8-week exploratory experimental study was conducted with young adults aged 19-39 years. Participants used a smartphone app in which EMA/EMI modules had been integrated with a smartwatch that continuously collected digital phenotyping data, including heart rate, sleep, and activity. Psychological outcomes were assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) at baseline and weeks 2, 4, 6, and 8, and the Rosenberg Self-Esteem Scale (RSES) at baseline and week 8. Quantitative changes were analyzed using paired-samples t tests and repeated-measures ANOVA, and qualitative interviews were thematically analyzed to identify user experience mechanisms and design implications.
Results
In all, 29 participants were included in the final analysis. Significant improvements were observed in their GAD-7 (mean difference -4.79, 95% CI -6.56 to -3.02; Cohen d=1.03; P<.001), PHQ-9 (mean difference -3.86, 95% CI -5.79 to -1.93; Cohen d=0.76; P<.001), and RSES scores (mean difference +5.21, 95% CI 3.47 to 6.95; Cohen d=1.14; P<.001). Consistent improvements in GAD-7 scores were observed across the assessment points, with statistically significant reductions from week 4 onward. Participants demonstrated high adherence, completing 80% of the EMA/EMI prompts. The digital phenotype showed trends of increased deep sleep and reduced mobility, and sleep indicators were significantly correlated with depressive symptoms. Analysis of the interview findings revealed 5 mechanisms: enhanced self-awareness, data-driven reflection, behavioral change, intrinsic motivation, and extension of treatment into daily life.
Conclusions
EMA/EMI-based digital therapeutics integrated with wearable-derived digital phenotypes are feasible and acceptable for use by young adults and were associated with within-group reductions in anxiety, suggesting acceptable efficacy, though this warrants confirmation in a controlled trial. The combination of real-time self-reported assessments of emotional states and passive physiological monitoring enables personalized feedback suited to users' emotional and physiological states. These findings offer empirical and design insights for automated, personalized mental health intervention systems.
来源与署名
Integration of Ecological Momentary Assessment and Intervention With Wearable-Based Digital Phenotypes to Treat Anxiety in Young Adults: Mixed Methods Experimental Study.
Song H, Choi Y, Park J, Hwang H, Kim J, Park C.
JMIR mHealth and uHealth · 2026-10-08
DOI: 10.2196/88919 ↗PubMed · 42849895 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
加速度计处理方法不同,身体活动与卒中、心肌梗死的关联曲线也不同
在英国生物银行中,基线无心血管疾病的90237名成年人随访至2022年12月,共发生1298例卒中和2031例心肌梗死;中高强度身体活动(MVPA)与这两种结局的关联曲线形状,取决于加速度计数据的处理方法。就卒中而言,只有机器学习法得到直线下降的风险;就心肌梗死而言,机器学习法和LFENMO法呈曲线下降,活动计数法呈直线下降。摘要没有给出风险比,只能说明不同方法的结论不一致,不能说明哪种方法更正确,而且这些只是观察性关联。
Preventive Medicine
智能手表数据能当“证人”吗:心率验证得最充分,其余证据参差
一项围绕数字取证展开的系统评价和荟萃分析,梳理了四大主流品牌智能手表的验证研究,发现心率是研究最多、也最准确的指标。步数、距离、能量消耗、活动分类和睡眠的验证不够一致,结果因品牌、方案和报告方式而异。摘要没有给出汇总数据,且多数研究是在健康人群中、于实验室内完成的,所以无法说明某一块手表对某个人在日常生活中的表现。
Forensic Science International
活动追踪器:每天多走约1800步,对其他健康指标影响较小
这项伞形综述汇总了39篇系统评价和荟萃分析,涉及163992名参与者;结果显示使用活动追踪器与身体活动增加相关(标准化均数差SMD为0.3–0.6),相当于每天多走约1800步、多步行40分钟,体重减轻约1公斤。对血压、胆固醇、糖化血红蛋白、生活质量和疼痛的影响通常很小,且多数不显著。摘要没有说明这些项目里追踪器还搭配了什么,也没有说明各评价之间重叠多少,因此不能把效果完全归功于设备本身。
The Lancet Digital Health
七款睡眠追踪设备:识别睡着很准,识别醒着和睡眠分期较差
在睡眠实验室里,34名健康的年轻成年人连续三晚佩戴七款消费级睡眠追踪设备中的若干款。与多导睡眠监测相比,所有设备识别睡眠都很准(灵敏度均不低于0.93),但识别清醒较差(特异度0.18–0.54),七款中有五款与研究用活动记录仪(特异度0.39)持平或更好;睡眠分期的估计结果不稳定。受试者是18至35岁的健康成年人,卧床时间固定为8小时,每款设备只在其中11至20人身上测试,因此对有睡眠问题的人几乎没有参考价值。
Sleep

